ArticleDiabetologia2010
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.
Article in Diabetologia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- [Individualizing antihypertensive therapy in diabetes mellitus. Guidelines of the Austrian Diabetes Association (Update 2026)].Wiener klinische Wochenschrift · 2026Guideline
- [Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (update 2023)].Wiener klinische Wochenschrift · 2023Guideline
- Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes care · 2012 · on this mapGuideline
- The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine.Diabetes care · 2011Trial
- The Application of Omics Technologies in Type II Diabetes Mellitus Research.Current diabetes reviews · 2026Review
- Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.Cardiovascular diabetology · 2020Article
- [Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (Update 2019)].Wiener klinische Wochenschrift · 2019Review
- Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies.Diabetologia · 2018Review
- Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes.Cardiovascular drugs and therapy · 2017Article
- Review
- Role of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: a narrative review.Journal of diabetes · 2014Review
- Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach.Pharmacogenomics and personalized medicine · 2014Review
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2013Article
- Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.Diabetes care · 2013 · on this mapArticle
- Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2013Article
- Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial.Current diabetes reports · 2013Review
- [Current treatment of type 2 diabetes].Der Internist · 2012Article
- Article
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia · 2012 · on this mapArticle
- The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.Diabetes, obesity & metabolism · 2012Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabetes complications and cardiovascular risk. This paper critically assesses the basis of the ADA/EASD algorithm and the resulting tiers of treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.